ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the first quarter 2024 after the U.S. market close... Read More